sequence stringlengths 4 17.9k | seq_id stringlengths 1 6 | pn stringclasses 996
values | title stringclasses 871
values | pbdt int64 20.2M 20.3M | status int64 1 225 ⌀ | family_country listlengths 1 55 | modified_info stringlengths 112 8.31k ⌀ |
|---|---|---|---|---|---|---|---|
tcccagtttcttgagatctga | 305 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 305 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 755 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 755 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 755 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 1873 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 1873 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 1873 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 485 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 485 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 485 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 2938 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 2938 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 2938 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 1197 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 1197 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 1197 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 923 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 923 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 923 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 35 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 35 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcccagtttcttgagatctga | 35 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttagccttcctctgaaggcattt | 1340 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttagccttcctctgaaggcattt | 1340 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttagccttcctctgaaggcattt | 1340 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttagccttcctctgaaggcattt | 1066 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttagccttcctctgaaggcattt | 1066 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttagccttcctctgaaggcattt | 1066 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atctacctaaagcagcatatttt | 2711 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atctacctaaagcagcatatttt | 2711 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atctacctaaagcagcatatttt | 2711 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcacttgtacgccatggaagagc | 1349 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcacttgtacgccatggaagagc | 1349 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcacttgtacgccatggaagagc | 1349 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcacttgtacgccatggaagagc | 1075 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcacttgtacgccatggaagagc | 1075 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcacttgtacgccatggaagagc | 1075 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttaccatgtattcacttcagtga | 1296 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttaccatgtattcacttcagtga | 1296 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttaccatgtattcacttcagtga | 1296 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttaccatgtattcacttcagtga | 1022 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttaccatgtattcacttcagtga | 1022 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttaccatgtattcacttcagtga | 1022 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
cagaagttgttagtgatttgcta | 2627 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
cagaagttgttagtgatttgcta | 2627 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
cagaagttgttagtgatttgcta | 2627 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atgtggatacaaattctccta | 2006 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atgtggatacaaattctccta | 2006 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atgtggatacaaattctccta | 2006 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atgtggatacaaattctccta | 3071 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atgtggatacaaattctccta | 3071 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atgtggatacaaattctccta | 3071 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aactatgcacctataaataca | 3159 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aactatgcacctataaataca | 3159 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aactatgcacctataaataca | 3159 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aactatgcacctataaataca | 1927 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aactatgcacctataaataca | 1927 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aactatgcacctataaataca | 1927 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aactatgcacctataaataca | 2992 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aactatgcacctataaataca | 2992 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aactatgcacctataaataca | 2992 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aactatgcacctataaataca | 2094 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aactatgcacctataaataca | 2094 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aactatgcacctataaataca | 2094 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
catggatgtattcatgaaaggac | 2764 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
catggatgtattcatgaaaggac | 2764 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
catggatgtattcatgaaaggac | 2764 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
cctgaagcctaagaaatatcttt | 2571 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
cctgaagcctaagaaatatcttt | 2571 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
cctgaagcctaagaaatatcttt | 2571 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
caatgaggcttatgaaatgca | 3127 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
caatgaggcttatgaaatgca | 3127 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
caatgaggcttatgaaatgca | 3127 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
caatgaggcttatgaaatgca | 2915 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
caatgaggcttatgaaatgca | 2915 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
caatgaggcttatgaaatgca | 2915 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
caatgaggcttatgaaatgca | 2062 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
caatgaggcttatgaaatgca | 2062 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
caatgaggcttatgaaatgca | 2062 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
caatgaggcttatgaaatgca | 1850 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
caatgaggcttatgaaatgca | 1850 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
caatgaggcttatgaaatgca | 1850 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atggttaccatagaaacttcctt | 2876 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atggttaccatagaaacttcctt | 2876 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
atggttaccatagaaacttcctt | 2876 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ctactacagagtgctaagcta | 2117 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ctactacagagtgctaagcta | 2117 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ctactacagagtgctaagcta | 2117 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ctactacagagtgctaagcta | 3182 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ctactacagagtgctaagcta | 3182 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ctactacagagtgctaagcta | 3182 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
cagaatattctagacatgctagc | 704 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
cagaatattctagacatgctagc | 704 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
cagaatattctagacatgctagc | 704 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
cagaatattctagacatgctagc | 2812 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
cagaatattctagacatgctagc | 2812 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
cagaatattctagacatgctagc | 2812 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
cagaatattctagacatgctagc | 254 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
cagaatattctagacatgctagc | 254 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.